Hi @Bouncing
The next trial that will start later this year, is an adaptive 2/3 trial for which the FDA has already advised they will consider accelerated approval at the 24 week mid trial results. This I understand is reliant on gaining Orphan Drug Designation status. The shelf life is also considerable so making a bulk batch will not go to waste.
Cheers
Hi @Bouncing The next trial that will start later this year, is...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $71.26M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $119.0K | 679.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 235714 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 190570 | 5 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.0¢ |
Change
0.000 ( 2.86 %) |
||||
| Open | High | Low | Volume | ||
| 17.5¢ | 18.0¢ | 17.5¢ | 48353 | ||
| Last updated 15.51pm 24/05/2024 ? | |||||
| PAA (ASX) Chart |